These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16678059)

  • 1. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of thalidomide in androgen-independent prostate cancer.
    Cox MC; Dahut WL; Figg WD
    Urol Oncol; 2006; 24(3):246-9. PubMed ID: 16678058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 12. The present and future of angiogenesis-directed treatments of colorectal cancer.
    O'Dwyer PJ
    Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic strategies for cancer therapy (Review).
    Benouchan M; Colombo BM
    Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and Leukemia Group B trials for advanced prostate cancer.
    Small EJ; Dawson NA; Kantoff PW; Vogelzang NJ
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):28-31. PubMed ID: 8996582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in prostate cancer therapy.
    Yu EM; Jain M; Aragon-Ching JB
    Discov Med; 2010 Dec; 10(55):521-30. PubMed ID: 21189223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of anti-angiogenesis therapy for prostate cancer.
    Jiménez JA; Kao C; Raikwar S; Gardner TA
    Urol Oncol; 2006; 24(3):260-8. PubMed ID: 16678061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
    Roy V; Perez EA
    Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy for hormone-refractory prostate cancer].
    Tsushima T
    Nihon Rinsho; 1998 Aug; 56(8):2167-72. PubMed ID: 9750528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.